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GenetherapyisreachingastagewheresomeclinicalbeneﬁtshavebeendemonstratedonpatientsinvolvedinphaseI/IIclinicaltrials.
However, in many cases, the clinical beneﬁt is hardly measurable and progress in the improvement of gene therapy formulations is
hampered by the lack of objective clinical endpoints to measure transgene delivery and to quantitate transgene expression. However,
these endpoints rely almost exclusively on the analysis of biopsies by molecular and histopathological methods. These methods
provide only a limited picture of the situation. Therefore, there is a need for a technology that would allow precise, spacio-temporal
measurement of gene expression on a whole body scale upon administration of the gene delivery vector. In the ﬁeld of gene therapy,
ac o n s i d e r a b l ee ﬀort is being invested in the development of noninvasive imaging of gene expression and this review presents the
various strategies currently being developed.
INTRODUCTION
Gene therapy can be deﬁned as the introduction of
genetic material into cells for a therapeutic purpose. The
ﬁeld itself can be divided into ex vivo gene therapy, where
the target cells are taken from a patient, genetically en-
gineered and reinfused into the patient and in vivo gene
therapy, where the gene medicine formulation is directly
injected into the patient. There are now some reports
where clinical eﬃcacy [1, 2, 3, 4, 5]o re v e nc o m p l e t ec u r e
[6] have been demonstrated. However, these successes re-
mainexceptionalandthelargemajorityofphaseI/IItrials
have failed to demonstrate any objective clinical eﬃcacy.
Therefore, the challenges of the ﬁeld are to understand
the reasons for the ineﬃcacy of the current formulations
in order to develop new and more eﬃcient gene delivery
vectors. For this purpose, the deﬁnition of relevant clini-
calendpoints iscrucial.Currently,theseendpoints relyon
analysis of biopsies. From these patient samples, the pres-
ence and expression of the transgene can be detected by
PCR, RT-PCR, or histopathological methods and in some
casesenzymaticactivityofthetransgenecanbemeasured.
However, the information that can be gathered from this
type of approach is restricted to a few cubic millimeters of
biopsy material and, therefore, is only a partial reﬂection
of the real situation in vivo.
Ideally, the monitoring of transgene delivery and ex-
pressionshouldcoverthewholebody,shouldbenoninva-
sive and could be repeated over time in the same patient
to provide information on the location, magnitude, and
kinetics of gene expression. The availability of such non-
invasive techniques could be pivotal in the rational devel-
opment of new formulations designed to selectively target
particular tissues, organs, or disease sites and, therefore,
a signiﬁcant eﬀort is currently being invested by the
gene therapy community to develop in vivo, noninvasive
molecular imaging technologies.
METHODS TO DETECT GENE EXPRESSION IN VIVO
IN PRECLINICAL MODELS
As in the case of in vitro transfection experiments, de-
tection of gene expression in vivo requires a reporter gene
and a technology capable of detecting its activity or pres-
ence in a particular tissue and in a noninvasive way. Two
types of methodologies that are already used in medicine
for other purposes are currently being adapted to usage
in gene therapy: nuclear medical methods and magnetic
resonance tomography. More recently, a technology ex-
ploiting the fact that bioluminescence can travel through
tissues and be detected by very sensitive cameras has been
developed.
The general principle is that upon expression of the
reporter gene the biodistribution of a tracer molecule is
altered, leading to its local concentration at the site of
reporter gene expression. Three types of reporter genes
are currently being considered and developed: enzymes,
receptors, and transport proteins (Figure 1). A general
overview of the diﬀerent reporter genes (proven or po-
tential) is presented in Table 1.
Enzymes
The reporter gene can be an enzyme expressed in-
side the cell that alters a labelled compound. The most
common approach consists of the phosphorylation of a2003:2 (2003) In Vivo Noninvasive Imaging for Gene Therapy 93
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Figure 1. General principles of biological imaging. (a) Enzymes as reporter genes; upon expression of the reporter gene, the imaging
marker (M) that can freely cross the plasmic membrane is metabolised within the cell (the most commonly used enzymatic reaction
is a phosphorylation). As a result, the phosphorylated marker becomes incapable of recrossing the plasmic membrane and is trapped
within the cell. (b) Receptors as reporter genes; upon expression of the reporter gene, the imaging ligand (L) binds to its receptor,
resulting in the accumulation of the detectable ligand in the transduced tissue. This signal can be ampliﬁed when the receptor gets in-
ternalised. (c) Transporter as reporter genes; upon expression of the transporter, the imaging compound (C) is selectively transported
into the cell where it concentrates. Depending on its nature, the imaging tracer is either trapped into the cell, or released when the
extracellular concentration decreases (question mark), leading to a transient signal.
Table 1. Reporter genes and corresponding probes for in vivo imaging.
Reporter genes Mechanism Imaging agents Imaging References
Cytosine deaminase Deamination 5-[19F]ﬂuorocytosine MRS [50]
HSV1-tk Phosphorylation
[131I]FIAU, [131I]FIAU SPECT, gamma camera [51, 52]
[124I]FIAU PET [53]
[123/125I]FIAU Gamma camera [54]
[14C]GCV, [3H]GCV Autoradiography [55, 56]
[18F]GCV PET [57, 58]
[18F]PCV PET [14]
[18F]FHPG PET [59, 60]
[18F]FHBG PET [12]
HSV1-sr39tk Phosphorylation [18F]PCV, [18F]FHBG PET [10, 12, 61, 62]
D2R Receptor-ligand [18F]FESP PET [13]
Mutant D2R Receptor-ligand [18F]FESP PET [11]
Somatostatin receptor Aﬃnity binding
[111In]DTPA-D-Phe1-octreotide Gamma camera [63]
[64Cu]-TETA-octreotide Tissue dose counting [64]
[188Re]-somatostatin analogue,
Gamma camera [65, 66, 67] 99mTc somatostatin analogue
Na/I symporter Active transport [131I], [123I]
Gamma camera
[24, 30, 68]
PET [69]
Luciferase Luciferin reaction Bioluminescence CCD camera [41, 70]
Cathepsin D Quenched
Fluorescence activation CCD camera [71]
ﬂuorochromes
Metalloproteinase Quenched
Fluorescence activation CCD camera [72]
ﬂuorochromes
β-galactosidase Hydrolysis of EgadMe MRI [73]
β-glycoside bond
Mutated transferrin Receptor-ligand Tf-MION MRI [40, 74]
receptor
Creatine kinase Dephosphorylation Phosphocreatine MRS [75]
Arginine kinase Dephosphorylation Phosphoarginine MRS [76]
substrate that can cross the plasma membrane of mam-
malian cells. The phosphorylated product becomes inca-
pable of traversing the cell membrane and gets trapped
inside the cell.94 G. Vassaux and T. Groot-Wassink 2003:2 (2003)
The ﬁrst tracers were developed for cytosine deami-
nase[7,8]butcellularuptakeprovedslowandthissystem
was superseded by an evolution of tracers that have been
created forthe prodrug-activating enzyme herpessimplex
virus-thymidine kinase (HSV-1-Tk, [9]). In the search
for medications against herpes simplex virus, compounds
have been found that are preferential substrates for the
HSV-1-tk rather than for cellular thymidine kinase. Radi-
olabelled derivatives have been produced that can be used
for imaging. Currently, FPCV (8-[18F]ﬂuoropenciclovir)
is the tracer compound that enables the highest sensitivity
even with weak expression of HSV-1-tk. A mutated HSV-
1-tk (HSV1-sr39tk) featuring a higher speciﬁcity to acy-
cloguanosines such as FPCV provides a further increase
in sensitivity [10]. Adenoviral delivery of CMV-driven
HSV1-sr39tk probed with FHPG (9-[(3-[18F]ﬂuoro-1-
hydroxy-2-propoxy) methyl] guanine) induced uptake of
8.5%ID/g in the liver of nude mice if 2×109 plaque form-
ing units (pfu) were injected intravenously [11]. Follow-
ing intratumoural injection of a similar adenovirus at a
dose of 1 × 109 pfu an FHPG concentration of 6.3%ID/g
has been described [12]. Images can be obtained about
one hour after tracer injection [11].
Receptorbinding
Much experience exists in the imaging community
with tracers that bind to surface receptors. These recep-
tors can be expressed as transgenes and can serve as re-
porter genes together with their speciﬁc labelled ligand.
Dopaminereceptor
The dopamine D2 receptor can be expressed as a
transgene in the cell membrane to induce binding of the
ligandFESP(3-(2 -[18F]ﬂuoroethyl)spiperone)whichcan
be imaged by positron emission tomography (PET) [13].
Because ectopic expression of the D2 receptor sensitises
cells to circulating adrenergic signals, a mutated recep-
tor (D80RA) has been reported uncouples ligand binding
from intracellular signal transduction [11]. When nude
mice were intravenously injected with 2 × 109 pfu, ade-
novirus in which CMV drives either D2R or D2R80A,
binding of 17.5%ID/g liver of FESP was observed [11].
FESP requires about 3-hours binding time before obtain-
ing the image [11]. In a direct comparison of the D2 re-
ceptor/FESP combination and the HSV-1-tk/FPCV sys-
tem, similar results were obtained [14].
Somatostatinreceptortype2(SSTR2)
Radiolabelled somatostatin analogues, such as
[111In]octreotide, are routinely used in the clinic for the
detection of rare neuroendocrine tumours expressing
the SSTR2. Expression of the receptor in tissues by gene
delivery has been shown to lead to uptake of the ligand.
When subcutaneous tumours in nude mice were injected
with 1×109 pfu adenovirus carrying the sstr2 gene driven
by a CMV promoter, 8%ID/g located to the tumour if
probed with [99mTc]P2045, another somatostatin ana-
logue. The time delay between injection and imaging was
5h o u r s[ 15]. In another study, intraperitoneal injection
of 1×109 pfu of the same virus led to uptake of 2.2%ID/g
[99mTc]P2045 in an intraperitoneal nude mice model
for ovarian cancer [16]. The native SSTR2 activates
intracellular signalling pathways resulting in cell cycle
arrest [17]. The engineering of a mutated variant has
been recommended [11] although the potential growth
arrest properties of the SSTR2 receptor may be beneﬁcial
for application in cancer gene therapy [18, 19].
Transporterproteins:theNa/Isymporter(NIS)
Transport proteins have high speciﬁcity for certain
compounds and can be expressed in the cell membrane as
reporter genes. They use active transport to concentrate
the labelled compound in a deﬁned compartment such as
the cell cytosol.
Figure 1 illustrates the function of NIS in the thyroid
gland. Driven by the sodium gradient across the basal
membrane it transports iodide into the cytoplasm and
concentratesittwentytofortyfold[20].Iodidethenleaves
the cytoplasm entering the thyroid follicle through the
apical membrane by facilitated transport, a process which
involves at least one (pendrin) [21]. NADPH oxidase on
the luminal side of the apical membrane generates H2O2
whichoxydizesiodidetoiodinethroughtheactionofthy-
roperoxidase (TPO). TPO allows binding of iodide to the
tyrosine residues in the thyroglobulin present in the thy-
roid follicle. Iodine is therefore trapped in the thyroid fol-
licle and is organiﬁed.
SoonafterthecloningoftheratNISgenein1996[22],
imaging of the transgene in nonthyroid cells was demon-
strated by gamma camera [23]. Intratumoural injection
of 2 × 109 adenovirus, in which NIS expression is con-
trolled by the immediate-early CMV promoter control,
was shown to redirect 11%ID/g of the injected radioio-
dine to the tumour [24].
Imaging using NIS oﬀers several advantages. Iodide
is a tracer without requirement for radiochemistry and
this has signiﬁcant logistic and cost advantages. Decay-
ing isotope does not produce cold tracer but disappears
from the system. Iodide has several isotopes with dif-
ferent nuclear physical properties that are widely used
in diﬀerent imaging protocols. [99mTc]pertechnetate can
be used in place of iodide and is the tracer of choice
for thyroid scintigraphy. [188Re]pertechnetate, a power-
ful beta emitter, is transported by NIS in a similar way
to [99mTc]pertechnetate and has been suggested for tar-
geted radiotherapy delivering higher tissue doses than can
be achieved with 131I[ 25]. These two isotopes can eas-
ily be obtained from generators. However, one potential
limitation of the system is that NIS alone is incapable of
the organiﬁcation of iodide. Therefore, the accumulation
of iodide can be predicted to be a dynamic phenomenon,
largely dependent on the clearance of the tracer and for2003:2 (2003) In Vivo Noninvasive Imaging for Gene Therapy 95
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Figure 2. Imaging of hNIS expression by PET. Individual coro-
nal slices from PET images of two nude mice intravenously
treated with 5×107 GFU adenovirus in which a CMV promoter
drives hNIS expression (left) and a PBS-treated control (right)
followed, 72 hours later, by injection of [124I] iodide as a tracer.
In both pictures, the chosen slice lies at the level of the thyroid
region (T). Tracer is seen in the stomach (S) and in the bladder
(B) of the control animal. Tracer uptake in the treated animal is
in the upper abdomen consistent with adenoviral homing to the
liver (for detailed experimental conditions, see [69]).
which this clearance eﬀect will vary between organs. A
PET image is presented in Figure 2.
Transgeneswithcombinedtherapeutic
andinvivoimagingpotential
By deﬁnition, reporter genes should demonstrate a
total lack of toxicity. However, an attractive alternative
would be able to monitor the expression of a therapeutic
transgene. This would combine monitoring of gene ex-
pression with monitoring of the eﬃcacy of the treatment
whichhasimplicationsinreducingthecostoftheseexper-
iments. Such an approach has been developed in cancer
gene therapy where a large number of studies have aimed
to develop tracer compounds that could be used to de-
tect the activity of prodrug-converting enzymes (HSV-1-
tk, cytosine deaminase).
In this context, the potential of the human NIS gene
(hNIS) transfer for targeted radiotherapy has to be recog-
nised. Concentration of radioiodine for the treatment of
diﬀerentiated metastatic thyroid cancer has been success-
fully utilized since 1943 [26]. Several authors have re-
ported the eﬀect of high doses of radioiodine on exper-
imental tumours following expression of NIS [27, 28].
In some cases, tumour reduction was demonstrated in
permanently NIS-expressing cell lines [29]. The biolog-
ical half-life of radioiodine in these studies is usually
short [24, 30] and the beneﬁt of a therapeutic dose has
been shown in only one in vivo model [27]. From clin-
ical reports it is known that failures of radioiodine ther-
apy are linked to a short biological half-life of activ-
ity in the tumour [31] and pharmacological agents such
as lithium have been described to prolong the biologi-
cal half-life of iodide thyroid tissue [32]. Diﬀerentiated
thyroidtissuegenerallyexpressesNISandTPOandmain-
tains the capability of retaining activity by organiﬁcation.
Coexpression of thyroid peroxidase has recently been re-
portedinvitrobuttheeﬀectoniodide retentionislimited
[33, 34].
Finally, the somatostatin receptor SSTR2 has been de-
scribed to induce cell cycle arrest [17]a n dr e p o r t sh a v e
demonstratedthatthiseﬀectcanprovidetherapeuticben-
eﬁts in pancreatic carcinoma models [18, 19].
NON-NUCLEAR-MEDICINE METHODS
Nuclear medical methods currently oﬀer the greatest
potential to be translated into clinical applications. They
are highly sensitive, provide good time resolution, and ac-
ceptable spatial resolution. But alternative methods are
currently in development.
Magneticresonanceimaging(MRI)
MRI techniques have recently shown some remark-
able images at very high anatomical resolution in small
animals [35], during development [36, 37] and in clinical
practice. However, compared to nuclear techniques, the
temporal resolution remains limited and the detection of
the probes by MRI is several orders of magnitude lower.
In an attempt to improve the sensitivity of MR for gene
therapy applications, an engineered transferrin receptor
has recently been used to shuttle and accumulate supra-
magnetic nanoparticles into the cells [38]. The MR tracer
consists of 3nm monocristalline iron oxide nanoparticles
(MION), sterically protected by a layer of dextran [39].
These MION can be covalently conjugated to the human
holotransferrin (Tf-MION). The use of Tf-MION allows
an ampliﬁcation of the signal due to the fact that an aver-
age of 2064 Fe molecules are taken up through the trans-
ferrinreceptor,asopposedtotwomoleculesofFeinholo-
transferrin. Upon binding of the Tf-MION to the trans-
ferrin receptor, the complex is internalised and MION are
accumulatedintotheendosome.Theproofofprincipleof
noninvasive in vivo imaging of gene expression has been
demonstrated [40] but it is likely that the development
of complementary strategies will be necessary before MRI
imaging can be used as a gene therapy tool in the clinic or
even in preclinical models.
Detectionofbiolumunescence
Very recently, some highly sensitive devices capable of
detecting and quantifying bioluminescent light have been
designed. These devices are capable of detecting photons
that are transmitted through mammalian tissues from in-
ternal sources [41].Thisimagingofveryweakvisiblelight
is rendered possible by the use of charged coupled device
(CCD) cameras that include microchannel plate intensi-
ﬁers and liquid nitrogen-cooled detectors. This technol-
ogy aims at enhancing signal-to-noise ratio by decreasing
the background (cooling) or amplifying the signal (inten-
siﬁers). These instruments are now commercially avail-
able.96 G. Vassaux and T. Groot-Wassink 2003:2 (2003)
Table 2. Comparison between SPECT and PET.
Method Advantages Disadvantages In vivo animal use Clinical use
SPECT - resolution limited by
technology only
(submillimeter)
- low sensitivities
-c a nd i ﬀerentiate between
isotopes with diﬀerent
radiation energies
- 2D (planar images) and
reconstructed 3D
- semiquantitative data
only
- converted clinical
cameras (pinhole
collimator)
- dedicated
cameras evolving
- readily available and
in widespread use
- wide range of clinically
tested tracers
PET - high sensitivity
- 3D acquisition
- good resolution, but with
a physical limit
- quantiﬁcation possible
- short-lived isotopes
-i s o t o p e sp r o d u c e di n
cyclotrons
- expensive tracer
production
- expensive equipment
- higher tissue doses, but
balanced by higher
sensitivity
currently evolving:
-H I D A C
- microPET
-[ 18F]FDG becoming
routine in oncology
- special applications in
neurology and cardiology
The gene therapy applications of this technology use
luciferase genes as reporter genes. Upon addition of
luciferin,theproductoftheluciferasegeneproducesluni-
nescence. In addition, luciferin has shown a remarkably
good and rapid biodistribution that allows detection of
gene expression in vivo feasible [42]. Most commonly, the
ﬁreﬂy luciferase gene is employed but other luciferases
emit light at diﬀerent wavelengths. This allows the moni-
toring of diﬀerent transgenes, simultaneously in the same
animal [43]. More recently, this technology has been used
successfully in preclinical models of diseases [44, 45].
However, if this technology appears to be very eﬀective
in small animals (mice, rats), there is no evidence that
bioluminescence imaging will be adaptable to larger ani-
mals, where the distances between organs and the skin are
greater and, therefore, the photonic signal is scattered and
attenuated. In addition, the signal is bidimentional and
tomographic images cannot be obtained by this method.
Therefore, bioluminescence detection currently appears
to be limited to the laboratory. An exception to this could
be clinical gene therapy for skin or occular diseases in
whichthetargettissueisdirectlyaccessibletothedetector.
However, this assumption is highly hypothetical and, to
our knowledge, no clinical protocol for such human stud-
ies has been submitted to the regulatory bodies.
NUCLEAR MEDICAL DETECTION METHODS
The beneﬁts and shortcoming of two main nuclear
imaging technologies and their potential for application
in the laboratory animal and in the clinic are outlined
in Table 2. Nuclear medical methods of gene expression
imaging oﬀer suﬃcient sensitivity and currently hold the
best potential to be scaled up for use in patients. The
principle methods are gamma cameras, single photon
emission-computed tomography (SPECT), and positron
emission tomography (PET).
Singlephotonemission-computed
tomography(SPECT)
SPECT uses arrays of detectors to identify individual
photons emitted by the isotope independent of their di-
rection. A directed view is obtained by ﬁtting metal col-
limators. Acting like blinkers, they ﬁlter out all photons
not travelling in a certain direction (eg, either right angle
to detectors or through a pinhole) relative to the detector
panel. However, the greatest problem with SPECT in re-
spect to gene therapy applications is its lack of potential
for quantitation.
Positron-emittingtomography(PET)
Becauseofitspotentialintermsofquantitationaswell
as its high sensitivity, PET appears to be the technique of
choice to collect information on the location, magnitude,
and kinetics of gene expression upon delivery of genetic
material.
Detection in a PET scanner requires tracers that in-
corporate positron-emitting isotopes. These isotopes de-
c a yb yan u m b e ro fd i ﬀerent decay mechanisms. In a cer-
tain percentage of these decays, positrons are released.
The positron will travel for some distance, deﬁned by
its energy and by the surrounding matter, before being
annihilated when hitting an electron. Two photons of
511MeV are created by the annihilation event and these
travel in opposite directions at an angle of almost ex-
actly 180◦. PET scanner detectors register all events in
a ring of detectors around the radioactivity source but
process only events that occur simultaneously within a
certain time window (Figure 3c). The annihilation event
must have taken place on a line between these two
detectors recording the event. Reconstruction from the
raw data is performed by diﬀerent mathematical meth-
ods that can be either back-projections or iterative re-
construction methods. They diﬀer in their resolution,2003:2 (2003) In Vivo Noninvasive Imaging for Gene Therapy 97
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Figure 3. (a) A positron and a neutrino are released when a proton becomes a neutron. (b) Two annihilation photons travel away
from each other at 180 ± 0.25◦. (c) The scanner records simultaneous events within a 10–80ns time window. These are from true
coincidences, scattered coincidences, and random coincidences from independent annihilation events. Single events are not processed
further (see [77]).
Table 3. Energy and half-life characteristics of selected positron-emitting isotopes.
Isotope Half-life
Maximum positron Maximum range Spatial resolution Radiation dose with
energy (FWHM) internal intake{890}
18F 109min 0.63MeV 2.6mm 0.22mm 0.049mSv/MBq
11C 20min 0.96MeV 4.2mm 0.28mm 0.024mSv/MBq
13N 9.9min 1.2MeV 5.4mm 0.35mm n/a
15O 122s 1.74MeV 8.4mm 1.22mm n/a
82Rb 1.3min 3.15MeV 17.1mm 2.6mm n/a
124I 4.2d 2.14MeV ∼ 1.5mm 13mSv/MBq
64Cu 12.7h 3.3MeV 0.12mSv/MBq
120I 81min 5.6MeV n/a
resolution-noise ratio, contrast, and required processing
time [46].
Spatial resolution in PET imaging has a physical limit
(a) because of the distance the photon travels between the
nuclear decay and the annihilation event and (b) because
the angle between the two annihilation photons deviates
slightlyaround180◦ (Figure 3b).Theformerisinﬂuenced
by the choice of isotope (Table 3), the latter is improved
with smaller dimensions of the scanner. Spatial resolution
is also reduced by scattering of the photons in tissue al-
tering the angle between them (“Scattered,” in Figure 3c).
The statistical quality of the image reconstruction is re-
duced by photons that are simultaneously registered but
originate from diﬀerent events (“Random,” in Figure 3c)
and by multiple simultaneous registrations. Both (a) and
(b) increase when the count rate approaches the satura-
tion rate of the detection system.
Another artifact arises from attenuation of photons
when travelling through the tissue. Signals from near the
body surface and in the lungs are registered with relatively
higher intensity. This is of less importance for smaller an-
imals but for patient imaging attenuation correction can
be performed during image reconstruction.
Positron-emitting isotopes are generally short-lived
(Table 3). They are produced in cyclotrons that should
be near the laboratory or hospital where tracer synthe-
sis, transport, and application take place. Small variations
in timing have important consequences. The tissue dose
from positron-emitting isotopes is relatively high because
the energy of the positron is completely absorbed in the
tissue. This is balanced by a short half-life but is more
signiﬁcant for 124I with a relatively long duration in the
tissue.
HUMAN STUDY
The development of these new technologies is just
reachingtheclinicand,toourknowledge,onlyonereport
has been published on the use of in vivo molecular imag-
ing in clinical gene therapy [47]. This study was preceded
bytheestablishmentofthepharmacodynamicandbiodis-
tribution parameters of the radioactive tracer [124I] FIAU
(to monitor HSV-1-tk expression) in humans [48], with a
particular emphasis on the head region. This radioactive
tracer was shown not to be able to cross the blood-brain
barrier in normal brain but showed rapid and nonspeciﬁc
accumulation within recurrent glioma [48], demonstrat-
ing that [124I] FIAU was a useful tracer when the blood-
brain barrier was disrupted. In a follow-up study, this
tracer was used in a small clinical trial testing liposomal
intratumoural delivery of the HSV-1-tk gene to patients
withrecurrentglioma[47].Theauthorsdemonstratedac-
cumulation of [124I] FIAU, indicative of HSV-1-tk expres-
sion,intheimmediateperipheryoftheneedletractinone98 G. Vassaux and T. Groot-Wassink 2003:2 (2003)
out of ﬁve patients. In this patient, the overall therapeutic
eﬀect was limited to a portion of the tumour. However,
in the four remaining patients, histology sections of the
tumour showed a signiﬁcant decrease in the number of
proliferating cells. This observation tends to indicate that
a critical threshold of gene expression has to be reached
before HSV-1-tk-associated FIAU could be detected by
PET. The authors concluded that the extent of HSV-1-tk
expression appeared to predict the therapeutic response.
However, the overall [124I] FIAU accumulation, as well as
the therapeutic response were limited [47].
CONCLUDING REMARK
There is little doubt that using whole body, noninva-
sive imaging technology will help to design gene therapy
formulations tailored to target diseases. But the need for
clinicians to monitor gene expression, and more gener-
allytomonitorbiodistributionandpharmacodynamicsof
gene therapy formulations in a more precise and quanti-
tative way has been sadly highlighted by the death of Jesse
Gelsinger, who became the ﬁrst person to die from exper-
imental techniques of gene therapy. Following his death,
one of the recommendations of the Recombinant DNA
Advisory Committee (RAC) of the National Institute of
Health in the USA was to develop better ways for mea-
suring transgene expression in cells and tissues in order to
improve the safety of these interventions [49].
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